Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments: 2020-2024

Historic Short-term Investments for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $26.0 million.

  • Silence Therapeutics' Short-term Investments was N/A to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $26.0 million for FY2024, which is 29.66% down from last year.
  • As of FY2024, Silence Therapeutics' Short-term Investments stood at $26.0 million, which was down 29.66% from $37.0 million recorded in FY2023.
  • Silence Therapeutics' 5-year Short-term Investments high stood at $37.0 million for FY2023, and its period low was $1.9 million during FY2020.
  • In the last 2 years, Silence Therapeutics' Short-term Investments had a median value of $31.5 million in 2023 and averaged $31.5 million.
  • Within the past 5 years, the most significant YoY rise in Silence Therapeutics' Short-term Investments was -29.66% (2024), while the steepest drop was 29.66% (2024).
  • MRY analysis of 3 years shows Silence Therapeutics' Short-term Investments stood at $1.9 million in 2020, then surged by 1,829.60% to $37.0 million in 2023, then fell by 29.66% to $26.0 million in 2024.
  • Its Short-term Investments was $26.0 million in FY2024, compared to $37.0 million in FY2023 and $1.9 million in FY2020.